Oxford Spin-Out Just Raised $300M to Rewrite the Rules of Drug Discovery

Jan de Vries · 2026-10-16

OMass Therapeutics, a UK biotech spun out of Oxford University, just closed an oversubscribed $300 million Series C round. That's a huge vote of confidence for a company tackling some of the hardest targets in drug discovery. The round was co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings, with participation from Janus Henderson Investors, SV Health Investors, and Jefferson Life Sciences. All existing investors also joined, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and the University of Oxford. ### Why This Matters OMass isn't your typical biotech. Founded in 2016, it grew out of Professor Dame Carol Robinson's lab at Oxford, where she pioneered native mass spectrometry. The company's OdyssION platform uses that technology to study drug targets in their native environments—giving researchers cell-system fidelity with cell-free precision. That's a mouthful, but here's the simple version: they can see how drugs interact with targets in a more realistic setting, which is a big deal for tough targets that have historically been hard to drug. "This financing comes at an exciting point in OMass' evolution as we advance OMS1620 into the clinic," said CEO Ros Deegan. "We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programmes in endocrinology and immunology." The lead program, OMS1620, is a potential best-in-class MC2 receptor antagonist. It's being developed for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome—both serious conditions with limited treatment options. The funding will push OMS1620 through Phase 2 trials. ### A Wave of European Biotech Funding OMass' round is part of a broader surge in European therapeutics funding. In 2026 alone, several companies have raised significant rounds: - **Bionyra Pharma** (France): $156 million for inflammatory diseases - **Breye Therapeutics** (Denmark): $74 million for oral small-molecule pipeline - **STORM Therapeutics** (UK): $52 million - **Microbiotica** (UK): $46 million - **Mironid** (UK): $43.5 million - **Alchemab Therapeutics** (UK): $32 million - **Laigo Bio** (Netherlands): $6 million Together with OMass, these deals represent over $700 million in new financing reported in 2026. That's a lot of capital flowing into European biotech—and it's not slowing down. ### What Investors Are Saying "OMass leverages an experienced team and a clear vision for building a leading therapeutics company that translates complex biology into differentiated medicines for patients with significant unmet needs," said Evan Greif, Principal at Bain Capital Life Sciences. "We see meaningful potential for OMS1620 to improve the treatment for patients with CAH." Max Klement, Partner at Novo Holdings, added: "We are pleased to join a premier investor syndicate supporting OMass as the Company advances its breakthrough programs into the clinic." ### The Bigger Picture For those of us following the EU Inc proposal and European startup incorporation, this is a reminder of the continent's growing strength in biotech. The EU Inc proposal aims to make it easier for startups to raise capital across borders, and deals like this show why that matters. OMass' success isn't just about one company—it's about an ecosystem that's maturing. With more investors willing to back high-risk, high-reward science, Europe is becoming a serious player in the global therapeutics race. And for patients? It means new hope. OMS1620 could be a game-changer for people with CAH and Cushing's syndrome. That's the kind of outcome that makes all this funding news worth watching.